Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): Phase 2 trial Meeting Abstract

  

Authors:	Modi, S.; Stopeck, A.; Kinden, H.; Sugarman, S.; Ma, W.; Solit, D.; Kersey, K.; Johnson, R.; Hannah, A. L.; Hudis, C.
Abstract Title:	Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): Phase 2 trial
Meeting Title:	30th Annual San Antonio Breast Cancer Symposium (SABCS)
Journal Title:	Breast Cancer Research and Treatment
Volume:	106
Issue:	Suppl. 1
Meeting Dates:	2007 Dec 13-16
Meeting Location:	San Antonio, TX
ISSN:	0167-6806
Publisher:	Springer
Date Published:	2007-12-01
Start Page:	S269
End Page:	S270
Language:	English
ACCESSION:	WOS:000251398500756
PROVIDER:	wos
PUBMED:	17957466
DOI:	10.1007/s10549-007-9793-3
Notes:	--- - Meeting Abstract: 6066 - 30th Annual San Antonio Breast Cancer Symposium - DEC 13-16, 2007 - San Antonio, TX - "1" - "Source: Wos"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/25656